Skip to Main Content

Paper Details

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
Clin Cancer Res
77
2022
Author NameAffiliation
Daniel A PollyeaUniversity of Colorado
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
David A RizzieriNovant Health Cancer Institute
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
  • 1 - 4

Datasets

Release 1.2